News
MedPage Today on MSN5d
Targeted Treatment Improves Disability in Guillain-Barre SyndromeThe primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...
To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...
Peruvian authorities Saturday declared a 90-day nationwide sanitary emergency due to the “unusual increase” in cases of Guillain-Barré Syndrome, it was reported in Lima. As per President Dina ...
Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...
Jenna Jameson gave an update on her health on Tuesday, clarifying that her likely case of Guillain-Barré Syndrome is "NOT a reaction" to the COVID-19 vaccine. The former adult film star ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback